Buying Ecstasy online in Sousse

__________________________

📍 Verified store!

📍 Guarantees! Quality! Reviews!

__________________________

▼▼ ▼▼ ▼▼ ▼▼ ▼▼ ▼▼ ▼▼

▲▲ ▲▲ ▲▲ ▲▲ ▲▲ ▲▲ ▲▲

Buying Ecstasy online in Sousse

Official websites use. Share sensitive information only on official, secure websites. Despite substantial improvements in the success of treatments through assisted reproduction technologies ART , live birth rates remain constantly low, and practitioners are seeking aetiologic treatments to improve the outcomes. Local inflammatory response is believed to contribute to implantation failure, where prostaglandins may increase uterine contractions and decrease uterine receptivity, decreasing the possibility of an IVF cycle leading to successful embryo transfer. They are often offered in clinical practice to improve ART outcomes, but current robust evidence on their efficacy is lacking. We designed the search using standard Cochrane methods and performed it on databases from their inception to 20 February There were no restrictions by language or country of origin. We used standard methodological procedures recommended by Cochrane. We performed statistical analysis using Review Manager 5. We found 11 RCTs women suitable for inclusion in the review. Most studies were at unclear or high risk of bias. The main limitations in the overall quality of the evidence were high risk of bias, unexplained heterogeneity and serious imprecision and indirectness. There were no data on our primary outcome — live birth per woman randomised — in any review comparisons. The results were similar when two studies were excluded due to high risk of bias. Concerning the secondary outcomes, we are uncertain of an effect on clinical pregnancy rates RR 1. There were no cases of congenital anomalies during antenatal ultrasound screening of the women in one study. Only one study compared piroxicam with indomethacin: we are uncertain of an effect on ongoing pregnancy RR 1. Similar results were reported for clinical pregnancy RR 1. This is based on available data from RCTs, where very low quality evidence showed that there is no single outcome measure demonstrating a benefit with their use. Despite both clinical and laboratory efforts and improvements in the success of these treatments, pregnancy rates remain low. Local inflammatory response is believed to cause implantation difficulties for the embryo, through the action of prostaglandins. These substances mainly cause a differentiated local inflammatory response and uterine contractions during embryo transfer, inhibiting the embryo from implanting successfully. In clinical practice, they are often offered to improve ART outcomes, but evidence is based on various types of studies. Thus because there is lack of clear evidence, their efficacy and safety still remain controversial. In this Cochrane Review we have summarised the available evidence on the use of NSAIDs in infertile women undergoing IVF, in an attempt to identify gaps and limitations in our current understanding. We searched for and included studies irrespective of language and country of origin. Two review authors independently selected and evaluated studies, extracted data, and attempted to contact the authors of studies for which data were missing. We found 11 studies women ; data were not available in one study, so we analysed data on patients; two studies were published as abstracts in international conference reports; and we found one ongoing trial that met our inclusion requirements. Only one study compared piroxicam with indomethacin: we are uncertain of an effect on ongoing pregnancy and on miscarriage. This is based on available data from randomised controlled trials, where no single outcome reported in the studies demonstrated a benefit with their use. This is because of several limitations including poorly reported study methods, imprecision, small study numbers and low numbers of events reported. An IVF cycle involves ovulation stimulation, oocyte retrieval, fertilisation and embryo transfer Speroff With the exception of fertilisation, each of these steps may lead to pain, with a localized inflammatory response and, sometimes, uterine contractions. Studies involving the use of aspirin in ART have not been considered, since a previous review showed clear evidence of no effect of aspirin for this purpose Siristatidis In cells, these enzymes are involved in the synthesis of prostaglandins. Prostaglandins are a group of chemicals produced by various cells in the body. They promote inflammation, pain and fever. The two main adverse drug reactions linked with NSAIDs are gastrointestinal and renal effects, and are associated with the different roles and tissue localisations of each COX isoenzyme Baigent ; Green ; Hawkey Each step of an ART cycle, with the exception of fertilisation, may lead to pain due to the inflammatory reaction. This reaction leads to the production of inflammatory cytokines, which in excess may be detrimental Chaouat Similarly, it is known that an inflammatory response produces prostaglandins locally, which may increase uterine contractions and also decrease uterine receptivity. These products are inexpensive and simple to use, yet remain controversial because of a lack of robust evidence for their efficacy and safety. In this Cochrane Review we have summarised the available evidence on the use of NSAIDs in subfertile women who are undergoing ART and tried to identify any gaps or limitations in our current understanding. Our aim is to provide a clear view on the effectiveness of this pharmacological intervention in order to encourage or disprove its clinical application. All randomised controlled trials, published or unpublished, comparing the relative effectiveness or safety of one of the interventions compared to the other treatment. We did not include the comparison of aspirin versus placebo, as this was the topic of another Cochrane Review Siristatidis Live birth or ongoing pregnancy rate per woman randomised: we defined live birth as delivery of a live fetus after 20 completed weeks of gestation; we defined ongoing pregnancy as a pregnancy beyond 12 weeks of gestation. Miscarriage rate per woman randomised, defined as the number of pregnancies lost before 20 weeks of gestation. Clinical pregnancy rate per woman randomised, defined as evidence of a gestational sac on ultrasound. Adverse effects to the woman per woman randomised: ectopic pregnancy, multiple birth, antenatal and perinatal complications. Adverse fetal effects including fetal anomalies chromosomal, congenital and anatomical abnormalities, preterm labour, growth restriction. Two review authors DV and IM independently conducted a systematic search of the published and unpublished literature. There were no restrictions on language or publication status. We developed the key search terms in accordance with the structured question. We identified synonyms and related terms for each of the PICO elements and added them to the strategy. We identified the relevant subject indexing terms used within individual databases and added them to the strategy as appropriate. We used database facilities, such as truncation, explosion and proximity searching, when they were available. We selected search filters from the ISSG search filter web site, for other databases and to identify systematic reviews www. We sought relevant publications in all languages including full papers and abstracts. Trial registers for ongoing and registered trials: Current Controlled Trials www. PubMed www. Professional societies, organisations and individuals e. We asked external referees who are experts in this field to check the completeness of the search strategy, and to identify any additional, ongoing and planned trials. We handsearched the reference lists from all searched published articles for additional studies. We also contacted experts in the subject area for further references. Similarly, we handsearched the conference proceedings and abstracts not covered in the CGF Specialized Register of Controlled Trials for relevant unpublished reports, theses and any other sources of potentially relevant references or studies, in liaison with the CGF Trials Search Coordinator. This form included details and criteria of all relevant trial characteristics Appendix 9 , Appendix Two review authors AN and DV reviewed titles and abstracts of references for compliance with the inclusion criteria for the review and excluded those considered irrelevant at this screening stage. We sought further information from the study authors when papers contained insufficient information to make a decision about eligibility. We documented the reasons for excluding any studies identified by the search in the ' Characteristics of excluded studies ' table. Two review authors AN and DV independently extracted data from the included studies using the standardized data extraction form Appendix Where there were insufficient data to enable us to make a decision on inclusion or exclusion, we included the trial provisionally and contacted the authors of the trial report for further data on methods or results, or both. AN and CS independently assessed the risk of bias for each trial using Cochrane's 'Risk of bias' assessment tool Higgins We resolved differences of opinion through discussion. We assessed whether adequate steps were taken to reduce the risk of bias across six domains: sequence generation; allocation concealment; blinding of participants, personnel, and outcome assessors ; incomplete outcome data; selective outcome reporting; and other sources of bias. For sequence generation and allocation concealment, we reported the methods used. For blinding, we described who was blinded and the blinding method. For selective outcome reporting, we stated any discrepancies between the methods used and the results, in terms of the outcomes measured or the outcomes reported. For other biases, we described any other trial features that we thought could affect the trial result e. We categorized our judgements as 'low risk of bias', 'high risk of bias', or 'unclear risk of bias', and this information was used to guide our interpretation of the presented data table, which was incorporated into the interpretations of review findings by means of sensitivity analyses. Where our judgement was unclear, we contacted the trial authors for clarification and resolved any differences of opinion through discussion. The 'Risk of bias' tables describe all judgements and present our conclusions; for summaries see Figure 2 and Figure 3. Methodological quality graph: review authors' judgements about each methodological quality item presented as percentages across all included studies. Methodological quality summary: review authors' judgements about each methodological quality item for each included study. For dichotomous data we used the number of events in the control and intervention groups of each study to calculate the risk ratio RR. There were no continuous data. All analyses were per woman randomised. As we were considering pain as an outcome we anticipated that we would have to convert different pain scales; this, however, was not the case. We assessed the characteristics of the included studies to decide whether there were sufficient similarities — in study populations, methodologies used, comparisons applied vs. If this had been found, we had planned to explore this by means of sensitivity analysis, as described below. We aimed to minimise publication and other biases and their potential impact by ensuring a comprehensive search for eligible studies and by being alert for duplication of data. We gave included trials an identity code, comprising the first author and the year published, and listed them in chronological order in forest plots. The review authors planned the following steps if, after confirming data, they detected substantial heterogeneity. Consider completing a subgroup analysis, according to meaningful factors, such as number of embryos transferred, previous failed cycles, maternal age, duration of treatment; and type of COX inhibitors. If we detected substantial heterogeneity, we explored possible explanations in subgroup analyses e. We took any statistical heterogeneity into account when interpreting the results, especially if there was any variation in the direction of effect. We planned sensitivity analyses for the primary outcomes and clinical pregnancy rates to determine whether the conclusions were robust to arbitrary decisions made regarding the eligibility and analysis. These analyses would have included consideration of whether the review conclusions would have differed if:. This table presents the overall quality of the body of evidence for the main review outcomes live birth, ongoing pregnancy, miscarriage, clinical pregnancy, multiple pregnancy, adverse effects for each comparison. We assessed the quality of the studies using five GRADE criteria: study limitations, consistency of effect, imprecision, indirectness, and publication bias Higgins Two authors independently assessed the quality of the evidence for each outcome. We justified, documented, and incorporated judgements about the quality of the evidence high, moderate, low or very low when reporting the results for each outcome. From the database search we located a total of titles and abstracts that we thought might provide data addressing our question of interest. Eleven proved to be duplicates and were not relevant: we excluded them based on the abstract. There was one ongoing study NCT Of the 11 included studies, two were published as abstracts at conferences Asgharnia ; Fekih see Characteristics of included studies. The included studies involved subfertile women undergoing ART; after subtracting the participants studied in Asgharnia , whose data were not available, we analysed data on women. All IVF cycles were fresh, except from one study, which reported on fresh and frozen embryos Moon Six studies were performed on piroxicam administered at a dosage of 10 mg once at 1 to 2 hours before embryo transfer Asgharnia ; Dal Prato ; Firouzabadi ; Kumbasar ; Moon ; Sohrabvand In one study patients received an oral dose of mg of ibuprofen 90 minutes before embryo transfer Fekih ; in a second, flurbiprofen axetil as a single dose 30 minutes before oocyte retrieval Zhao ; and in a third, sodium dilclofenac suppository was administered at a dosage of mg at the end of oocyte retrieval Kailasam Piroxicam was compared with indomethacin, and the exact interventions have been described above Kumbasar In the comparison between piroxicam versus indomethacin, Kumbasar reported ongoing pregnancy, miscarriage and clinical pregnancy. Of the records identified after removal of duplicates, we excluded studies initially on the basis of the abstract Figure 1. We describe the 'Risk of bias' assessments in detail in the 'Risk of bias' tables in Characteristics of included studies , and in Figure 2 and Figure 3. We made the decisions after sending emails to the study authors in an attempt to retrieve further data. Random sequence generation was at unclear risk of bias in three studies Fekih ; Kumbasar ; Sohrabvand ; at high risk of bias in two Asgharnia ; Sohrabvand ; and at low risk in the rest of the included studies. Blinding of participants was at high risk of bias as it was not performed in one study Dal Prato , where authors stated that it was not possible to provide a placebo, and not described in an abstract Asgharnia , and two full text articles Kumbasar ; Sohrabvand Blinding of outcome assessment was at low risk only in one study Zhao , while most of the studies were at high risk. Reporting bias was low in four studies, and high in the two which were published as abstracts Asgharnia ; Fekih No other sources of bias were identified in four studies Dal Prato ; Firouzabadi ; Kailasam ; Zhao See: Table 1 ; Table 2. There were four studies reporting ongoing pregnancy. Four studies reported this outcome: three of them involved the use of piroxicam Dal Prato ; Firouzabadi ; Kumbasar ; one involved the use of indomethacin Kumbasar ; and one involved the use of ibuprofen Fekih A total of seven studies reported on clinical pregnancy. One study used diclofenac Kailasam ; four used piroxicam Dal Prato ; Firouzabadi ; Kumbasar ; Moon ; one study used indomethacin Kumbasar ; one study used flurbiprofen axetil Zhao ; and one used ibuprofen Fekih There were five studies reporting adverse effects in pregnancy. Only one study involving piroxicam reported this outcome Dal Prato There was no certainty of an effect in ectopic pregnancy when piroxicam was compared to placebo RR 0. Only one study involving piroxicam reported this outcome Firouzabadi There was no certainty of an effect in multiple pregnancy rate when piroxicam was compared to placebo RR 2. In the first study, side effects related to indomethacin included headache, gastrointestinal complaints, nausea and dizziness; in the second, although authors reported the presence of muscle cramps in the control group, there were no events observed in the indomethacin group; in the third study, authors reported no side effects in either compared groups. Apart from the fact that side effects were minimal and different among studies, we are unable to account further for this heterogeneity Analysis 1. There were no congenital anomalies reported during antenatal ultrasound screening in both groups Kumbasar One study compared piroxicam with indomethacin Kumbasar There was no certainty of an effect in ongoing pregnancy when piroxicam was compared with indomethacin RR 1. There was no certainty of an effect in miscarriage when piroxicam was compared with indomethacin RR 1. There was no certainty of an effect in clinical pregnancy when piroxicam was compared with indomethacin RR 1. After analysis of the data, we are uncertain of the effect of NSAIDs on ongoing pregnancy, as the studies were at high risk of bias and pooled estimates were imprecise. Three of them involved the use of piroxicam Dal Prato ; Firouzabadi ; Kumbasar ; one involved the use of indomethacin Kumbasar ; and one involved the use of ibuprofen Fekih After analysis of the data, we are uncertain of the effect of NSAIDs on miscarriage, as the studies were at high risk of bias and pooled estimates were imprecise. We did not find different results when we removed data from RCTs with high risk of bias in our sensitivity analysis for miscarriage and when we performed subgroup analysis of ongoing pregnancy according to the type of NSAID used. There were sparse data for adverse fetal effects, quality of life and relief of pain in this comparison. In the second comparison of this review, we found one study comparing piroxicam with indomethacin Kumbasar : we found very low quality evidence of no certainty of an effect in ongoing pregnancy, miscarriage and clinical pregnancy rates. Data on other secondary outcomes set for this review were not available, apart from the adverse fetal effects that were reported as null in both groups. We included 11 studies with data relevant to the review question and a total of women in this Cochrane Review. Women eligible for randomisation had an average age of less than 35 years; they were defined as infertile women with an expected good prognosis in terms of ovarian response after stimulation. These studies reported on outcomes which included ongoing pregnancy and miscarriage amongst primary outcomes and clinical pregnancy, adverse effects to the woman including ectopic and multiple pregnancy, drugs side effects and fetus chromosomal abnormalities and relief of pain amongst secondary outcomes. Of note: none of them reported on live births. All studies were conducted in an urban setting in IVF units in countries around the world. Participants suffered from infertility from the conventional causes and seemed to be good responders. There were no data on high or poor responders, or in specific categories of infertile patients, such as those with recurrent implantation failures. In addition to the published data collected, we retrieved only a small amount of extra details on the trials after communication with authors: a lot of information is therefore missing in many cases. We had no data on the quality of life in the first comparison and in most of the secondary outcomes in the second. We found 28 potentially eligible studies. Of them, 11 studies were eligible for inclusion and 10 for further analysis. The overall quality ranged from very low for the primary outcomes in both comparisons and from very low to low for the secondary outcomes Table 1 ; Table 2 In addition to the published data collected, we retrieved some extra details by communicating authors of the original studies; specified information remained missing in many cases. Of note: one study was published only as a conference abstract. We found very low quality evidence for the secondary outcome of adverse effects, due to serious risk of bias including poor reporting of methods, attrition bias, selective reporting, and other biases, very serious indirectness, very serious imprecision and wide confidence interval. For fetal congenital abnormalities, we found one very low quality trial at high risk of attrition and reporting biases that investigated both review comparisons. It reported no events in either comparison. We made every effort to identify all eligible studies, following standard Cochrane procedures. We did not identify any potential source of bias, except from the fact that very few trial authors responded to our requests for additional information, and that, understandably, the data could not be retrieved for the ongoing trial. There are no similar reviews to date addressing this comparison. These drugs have been linked in the past with 'reversible female infertility' Stone , and are currently used in medical conditions pain due to endometriosis related to infertility Brown , primary dysmenorrhoea Marjoribanks , and in the management of uterine adenomyosis Vannuccini , amongst others. We found little evidence from properly conducted randomised controlled trials RCTs regarding the use of NSAIDs in infertile women undergoing assisted reproduction, in spite of some promising data in the literature, through their physiology and potential action on localized inflammatory response, delaying or preventing ovulation and uterine contractions during an IVF cycle. Individual studies have concluded that there was a reduction in miscarriage rates using ibuprofen and an improvement in clinical pregnancy rates using piroxicam when compared to placebo , but the synthesis of all included studies showed no evidence to support the use of NSAIDs. This could be due to the small number of eligible studies and variations in dose administration and time of treatment commencement across studies. In secondary outcomes for both comparisons, including clinical pregnancy, adverse effects to the woman and fetus, the quality varied from low to very low. We are awaiting the results of one ongoing trial, but it is unlikely that these could change the results of our review. We identified 11 studies: two were published in the form of abstracts and there was one ongoing study; data were available for 10 of them, including a total of women. After the synthesis of data, we arrived at no robust conclusions concerning their use. Notably, participants so far have been infertile women, relatively young and identified as normal responders to ovarian stimulation. Other subgroups, such as high or poor responders although in the latter there might be a restriction because of the low number of embryos anticipated , or even women with recurrent implantation failures, could be included in the trials. Accurate documentation of the randomisation, allocation concealment, and blinding methods is highly desirable, so that risks of bias could be eliminated and the quality of the conclusions could be at high levels. In addition to the primary outcomes of live birth and miscarriage, study protocols should include the reporting of other adverse effects, and of crucial secondary outcomes. In addition, we thank the authors of all included studies for supplying further information in response to our queries. We also thank Irene Moridi, Mina Mahdian and Miss Babalwa Zani for their contributions to the protocol and to early drafts of this review. Miscarriage rate was moved to the primary outcomes and clinical pregnancy rate was added to the secondary outcomes to provide a more meaningful approach to the research question. Adverse effects of the drugs administered were considered to have had a temporary effect on the quality of life of the patient, thus these were analysed in the relevant section. We conducted analyses using RR instead of OR because this is our preferred analysis method, as we estimate probability and not odds for the specific question of the review; notably, results were not affected using ORs. AN lead author: writing of the protocol, extracting data of included studies, conducting the analysis and drafting the manuscript. DV: extracting data of included studies, conducting the analysis and developing tables and figures. As a library, NLM provides access to scientific literature. Cochrane Database Syst Rev. Find articles by Atunga Nyachieo. Find articles by Charalampos S Siristatidis. Find articles by Dennis Vaidakis. Collection date This article is an update of the article with doi: Open in a new tab. If no then exclude. If yes go to questions 2 Yes No Unclear 2 Participants a Are participants subfertile women subfertile for any cause who were undergoing any form of assisted reproductive therapy ART which will included IVF, intracytoplasmic sperm injection, ovulation induction and intrauterine insemination? Yes No Unclear If 'no', exclude. Otherwise go to question 3. Yes No Unclear If 'no' to a or b , exclude. Final decision Include if all 'yes' Exclude if any 'no' Unclear Excluded or unclear because: If 'unclear', action taken:. Outcome or subgroup title No. Primary outcomes of the review were addressed Selective reporting reporting bias Unclear risk All data were reported and discussed according to the initially stated objectives of the study authors. No protocol provided Other bias Low risk No apparent evidence of other bias. Primary outcomes of the review were addressed Selective reporting reporting bias Unclear risk No protocol provided Other bias Low risk No evidence of any other source of bias. Not examined the primary outcome of interest of this review Selective reporting reporting bias Low risk None. Authors report all initially planned outcomes, including side effects Other bias Low risk No other sources of bias identified. In all participants, ETs were performed on day 2 following OR Outcomes The rates of implantation, ongoing authors define it after 24 weeks and clinical pregnancy and miscarriage. In the fresh ET cycles, the treatment group 94 cycles received an oral dose of 10 mg of piroxicam Brexin; Kolon Inc. In the frozen—thawed ET cycles, 39 cycles received 10 mg of piroxicam orally treatment group and 39 cycles were treated with placebo control group. Duration of infertility was 6. Similar articles. Add to Collections. Create a new collection. Add to an existing collection. Choose a collection Unable to load your collection due to an error Please try again. Add Cancel. Piroxicam compared to Indomethacin for assisted reproductive technology. Described as randomised? If yes go to questions 2. Include if all 'yes' Exclude if any 'no' Unclear. Primary outcomes Live birth Ongoing pregnancy number of pregnancies which continued beyond 12 weeks. Primary outcomes: pregnancy rate Secondary outcomes: mean number of oocyte retrieval metaphase II , 2 pn, embryo cleaved, embryo transferred. Ethics: an informed consent form was obtained from each participant Funding: supported by Azad Islamic university Rasht; Mehr Infertility Institute Sample size: not provided No adverse effects reported due to treatment Protocol of the study not provided, the study was published as an abstract in a conference meeting. Ethics: informed consent; approved by Institutional Review Board Funding: not stated Sample size provided No adverse effects reported due to treatment; ectopic pregnancies were reported Protocol of the study not provided. The randomisation list was provided by an external statistician. No blinding performed 'because it was not possible to provide a placebo', as authors stated. No participant was excluded from the final analysis. Primary outcomes of the review were addressed. All data were reported and discussed according to the initially stated objectives of the study authors. No protocol provided. Inclusion: women undergoing IVF because of tubal, male infertility, unexplained, or endometriosis factors Exclusion: not stated Baseline characteristics: not stated. Intervention: 83 women included in fresh ET cycles received an oral dose of mg of ibuprofen 10 drops ; while in the control group, the same number cycles corresponding to the treatment group were treated with placebo. Outcomes reported: pregnancy and implantation rates Secondary outcomes: abortion rates. Authors state that 'They were randomly divided into treatment and control group' in their abstract, but no further details were provided. Authors state that 'Patients and staff were blinded to the treatment' in their abstract. Pirmary outcomes: clinical pregnancy rate fetal heart at 8 weeks Secondary outcomes: implantation rates, multiple pregnancy, biochemical pregnancy, miscarriage rates. Ethics: written informed consent; approved by Institutional Review Board Funding: not stated Protocol: not stated. Participants and staff were blinded to the treatment, authors stated. No participant was lost and all data were reported. Norethisterone Pharmacia, UK 5 mg twice daily was administered orally for 7 days from day 19 of the preceding cycle to reduce the incidence of functional ovarian cysts Long luteal phase protocol. Ethics: the study was conducted following approval from the local research ethics committee and participants gave written informed consent for all clinical procedures Funding: not mentioned Protocol: not mentioned The study was performed at Centre for Reproductive Medicine, University of Bristol. A block randomisation list was used in order to balance the number receiving diclofenac sodium versus no treatment controls after every 20 women enrolled. Participants and nurses were blinded as regards diclofenac sodium administration. Not examined the primary outcome of interest of this review. Authors report all initially planned outcomes, including side effects. No other sources of bias identified. Intervention: the participants were divided randomly into 3 groups. In all participants, ETs were performed on day 2 following OR. The rates of implantation, ongoing authors define it after 24 weeks and clinical pregnancy and miscarriage. Also, authors reported adverse effects resulting from the use of piroxicam or indomethacin, and congenital anomalies observed during antenatal ultrasound screening. Auhtors stated that the participants were divided randomly into 3 groups, but no further information was available. Primary outcomes: implantation rate and clinical pregnancy rate Secondary outcomes: not reported. Author's response: centralized randomisation process; computer generated. Authors did not address the primary outcomes of interest of this review. Inclusion: women qualifying for IVF between 18 and 36 years and who had an ovulatory cycle between 26 and 35 days; no ovarian cysts; no previous IVF treatments except when this treatment had resulted in an ongoing pregnancy ; no contraindications for the use of indometacin e. Embryo transfer was performed on the 3rd day after OR. Randomisation done using SPSS statistical software with block randomisation. Participants and physicians unaware of treatment allocation. Authors include primary endpoints of this review and side effects. All primary and secondary outcomes were reported including adverse events. Trial funded by pharmaceutical company and the role of the funder was not described The sample size was calculated for the primary endpoint. Primary outcomes: biochemical pregnancy, abdominal muscle cramps Secondary outcomes: not mentioned. Not described and no response from authors on random sequence generation. Author's response: sealed, opaque, sequentially numbered, identical envelopes. Double blind mentioned though not described in detail how it was done. No missing participants, but the primary outcomes of the review were not included. Inclusion: age group of 20 to 35 years old and with ART indication due to tubal factors, ovulation disorders or severe male factor Exclusion: systemic diseases and endometriosis 50 women randomised. Intervention: Group A received piroxicam 10 mg, Tolid Daru, Iran orally 30 minutes before embryo transfer and group B did not use any form of medication which is the conventional method used control group. Mentioned in the text, but no further data are available. No missing participants, but the primary outcomes of the review were not addressed. Participants were prospectively allocated to 2 groups, the flurbiprofen axetil group FA group or the placebo group control group. Primary outcome parameters: pregnancy rate clinical Secondary outcomes: consumption of analgesic rescue, the number and grading of body movements during the procedure, postoperative pain score, and biomarker PGE2 concentration in follicular fluid, consumption of tramadol after being discharged. Provided by sealed envelopes from a nurse who was not involved in the actual conduct of the study. The study coordinator, attending anaesthesiologist, data collection resident, and the participants were all unaware of treatment group assignment. Akande Aldeery Bernabeu Bou Nemer Kadoch Kawachiya Lier Matsota Mesen Mialon Sallam Inadequate and vague description of methodology and results. Sarhan Seidler Shah Nawaz Study type: interventional clinical trial Allocation: randomised Intervention model: parallel assignment Masking: none open label Primary purpose: prevention. Endometrial pathology. Experimental: indomethacin 1 dose of indomethacin mg rectal suppository will be administered 1 to 2 hours before embryo transfer No intervention: no medication No indomethacine before embryo transfer.

Nonsteroidal anti‐inflammatory drugs for assisted reproductive technology

Buying Ecstasy online in Sousse

Traveler's tips about drugs in Sousse, Tunisia. This guide is about drugs in Sousse: weed, cocaine and MDMA - availability, prices, legal regulations, options to buy. From popular substances to hidden hotspots, this guide unveils the secrets of the Sousse drug culture. If you have prior experience obtaining mdma, cocaine or weed in Sousse , we invite you to share your insights in the comments section below. Your contribution will undoubtedly be valuable. Disclaimer: The information provided in this guide is for informational purposes only. We do not endorse or encourage any illegal activities. Everybody knows Sousse has crazy energy flowing. When it comes to drugs in Sousse , locals and cops usually keep it chill, with plenty of them smoking joints once in a while themselves. Speaking of scoring drugs in Sousse: these days you have Telegram bots, digital hustlers on WhatsApp and Telegram, and even drug-dealing websites hooking you up with whatever you want. Prepare to crypto payments and surf legit dealers in the chat apps and shady corners of the darknet. We're talking about something called cocaine in Sousse. It's kind of like a puzzle that lots of places have too. So, here's the fact: you might find not-so-good cocaine on the streets of Sousse, but something called 'amazing fishscale' — that's for locals who have special connections or those online dealers who are in the know. But here's a tip: if you're after the super good cocaine in Sousse - it's like a treasure hunt. Find a local barman, and they can give you dealer contacts or the website address where to find the best coke in Sousse. Just remember, it's all about being safe and finding the right people! If you aren't ready to ask someone in person where to buy good cocaine in Sousse, you should just find and ask local darknet websites. After finding an online dealer, be ready to pay in crypto. After payment your package will be delivered to the place you discussed previously. The package with coke may look like a beer can or even a small toy car, so no one around may suspect anything. The go-to form for this party and intimate enhancer is 'Ecstasy pills', but sometimes you might even find pure MDMA powder, keeping things extra real in Sousse. Ecstasy pills ain't just about one MDMA ingredient — they might toss in some extras like 2cb or amphetamine to level up the vibe for all-night clubbing and dancing marathons in Sousse. Whether you're copping that ecstasy goodness online in Sousse or making moves on the streets, one thing's for sure — you gotta roll with the good high quality stuff, cooked up in those Euro labs. In general in Sousse drug scene is presented by online dealers and websites, while street dealers still exist. Online drugs selling process in Sousse usually includes pre-payment in crypto with further delivery of a stealth package to destination point. To get some good quality vibe in Sousse just try hunting down local darknet sites or locking onto dealers in WhatsApp, Telegram, or Viber. Get plugged in and let the game come to you. If you have anything you can share, please kindly assist a brother in this quest. Good vibes and grace from Jah Rastafari to all of us! Much love and solidarity to everyone! OMG, can you believe it? I never thought I'd be getting my hands on LSD through a freakin' automated bot. But guess what? Life surprises you, my peeps! And let me tell you, fam, it's a total game-changer! In just a short while, it beamed me all the info I needed to score my cosmic ride. Talk about futuristic tripping, yo! Hi dudes I live in Sousse for more than 3 years already so I know local drugs scene. You will never find better stuff than Heisenberg who else lol sells. As all dealers he is sometimes slow in resonse and disappears during the day, but the quality of his stuff is really something outa this world, recommend. Please sign in to join the discussion. Thanks for signing up! Please check your inbox and confirm your account to sign in. I already have an account. A combination of email and password was not found in our system. Do not have an account? Getting high in Sousse: vibe check and finding stuff Everybody knows Sousse has crazy energy flowing. Checking out Cocaine in Sousse: what's the deal with Fishscale? Hunting HQ cocaine in Sousse If you aren't ready to ask someone in person where to buy good cocaine in Sousse, you should just find and ask local darknet websites. Scoring Top-Notch Ecstasy and MDMA in Sousse Whether you're copping that ecstasy goodness online in Sousse or making moves on the streets, one thing's for sure — you gotta roll with the good high quality stuff, cooked up in those Euro labs. Overall impression about drugs scene in Sousse In general in Sousse drug scene is presented by online dealers and websites, while street dealers still exist. Comments 13 my Rastafarian brothers and sisters! Oh yeah, sure, dealers are the most honest people in the world. All rights reserved.

Buying Ecstasy online in Sousse